ArticleExperimental & molecular medicine2026
Mcu regulates bone formation via mitochondrial calcium uptake and lineage allocation.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The mitochondrial calcium uniporter (Mcu) mediates calcium influx into the mitochondrial matrix, playing an essential role in cellular energy metabolism and survival. Although Mcu has been studied in various physiological contexts, its role in skeletal homeostasis remains poorly understood. Here we investigate how Mcu deficiency affects osteoblast differentiation and bone formation under aging-related stress. Using an inducible whole-body Mcu-knockout mouse model, we found that Mcu deletion resulted in impaired mitochondrial calcium uptake, reduced oxidative phosphorylation, fragmented mitochondrial morphology and decreased expression of osteogenic genes, leading to defective osteogenesis. Concurrently, adipogenic markers were elevated in Mcu-deficient bone marrow cells, indicating altered mesenchymal lineage commitment. Mechanistically, Mcu-deficient cells exhibited enhanced TGF-β signaling and reduced BMP/Wnt pathway activity. In vivo, inducible whole-body Mcu-knockout mice exhibited reduced trabecular bone volume and density while maintaining normal skeletal growth. Pharmacological modulation of mitochondrial calcium influx using kaempferol enhanced osteogenic differentiation and mitochondrial respiration in wild-type, but not Mcu-deficient, cells. Consistently, analysis of publicly available human datasets revealed age- and osteoporosis-associated downregulation of MCU expression in bone tissues. These findings suggest that Mcu regulates bone formation by controlling mitochondrial calcium uptake and mesenchymal lineage allocation. Targeting mitochondrial calcium signaling may offer novel therapeutic strategies for age-related skeletal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.